Treatment of colorectal cancer chemotherapy drugs

By | October 24, 2011

With the development of medical research and treatment of colorectal cancer chemotherapy drugs have been developed, the clinical treatment of colorectal cancer chemotherapy drugs are mainly the following:
Treatment of cancer chemotherapy drugs (a) oxaliplatin uranium (uranium oxalate, Oxaliplatin, L-OHP)
Shun is the second consignment sales and calipers after the third class of anti-cancer drugs, anti-cancer spectrum is not identical. Preclinical studies have shown that lead exposure on colon cancer cell line oxaliplatin and cis lead resistance and other tumor cell lines significantly inhibited. I clinical trial showed that dose-limiting toxicity of oxaliplatin uranium insensitive to acute and cumulative transient peripheral neurotoxicity, a few months after cessation of treatment can be resumed. Oxaliplatin uranium to 130mg / time, every 3 weeks, or 85mg / when repeated every 2 weeks (intravenous infusion for 2 hours) when the recommended dose, no ototoxicity, renal toxicity, and dose-limiting toxicity of blood . H clinical trial of single-agent treatment in advanced colorectal cancer who received 5-Fu treatment or drug and had not received 5-Fu treatment objective response rate was 10% and 20%. Preclinical studies have shown that uranium and thymus slightly Xiao oxaliplatin synthase inhibitor, JI Fortunately or cards from the uranium, CTP-ll in combination have synergistic cytotoxicity.
Treatment of colorectal cancer chemotherapy drugs (b) Shannon irinotecan (Irinotecan, CTP-11)
Is an inhibitor of topoisomerase I, II clinical study showed that treatment of colon cancer without the effective rate of 20% of patients on 5-Fu resistance to the effective rate of 15% – 25%. CTP-ll the main side effects are mild neutropenia and diarrhea, severe degree of acid-based drugs wake up the degree of glucose and its metabolite SN-8 of the volume. CPT monotherapy for a 11 as second-line colorectal cancer treatment. According to the results of clinical trials E, Europe and the United States has approved the Joint 5 CPT-II in the u / LV as first-line treatment of colorectal cancer treatment.
Treatment of colorectal cancer chemotherapy drug (c) capecitabine (Capecitabine, Xelo towels, Xeloda)
Has the following characteristics: the first that oral amino acid fluorouracil slightly Anhui enzyme, can simulate the continuous infusion of 5-Fu and play a role in anti-tumor, tumor cells activated to enhance the efficacy and reduce toxicity. Of capecitabine for three different applications of a randomized clinical trial of H results show that the rates were 21%, 23% and 24%, and according to a longer time to disease progression CTTP), tolerability and therapeutic index, etc., to determine inter-Xie Kapei program gemcitabine monotherapy (treatment 2 weeks interval of 1 week) clinical trial as a dish using the best option. A total of 1207 cases of two multicenter randomized field trial of capecitabine alone compared with 5-Fu / A cool tetrahydrofolate CCF) as first-line treatment of metastatic colorectal cancer showed that capecitabine was effective 25.7% ,5-Fu / CF was 13.2% CP <0.0002), survival and disease progression was similar. Slight toxicity, mainly diarrhea and hand-foot syndrome. Specific programs are as follows: capecitabine 1250mg/Cmzed), 2 times a day [C total dose 2 500mg Cmz / ed)], orally for 14 days, rest 7 days, 21 days.
Treatment of colorectal cancer chemotherapy drug (IV) Tomudex CRaltitrexed)
Lin is the cha lag folate isomers of the same work, is a strong acid synthase chest selective inhibitor celecoxib. Zalcberg et al reported in a clinical study showed that E, 176 cases of untreated metastatic colorectal cancer patients received the drug treatment, the real effective rate of 26%, the median survival was 42 weeks. The main side effects were fatigue, diarrhea, leukopenia and asymptomatic transaminase elevation.

Leave a Reply

Your email address will not be published. Required fields are marked *